GSK spin-off NeRRe raises £23 million
UK clinical-stage group NeRRe Therapeutics has raised £23 million advance its unique neurokinin receptor antagonist pipeline towards late-stage clinical development.
Read More
Tag: NK-1 antagonist
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
